These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 18687892)

  • 21. Activation by Oxidation: Ferrocene-Functionalized Ru(II)-Arene Complexes with Anticancer, Antibacterial, and Antioxidant Properties.
    Mu C; Prosser KE; Harrypersad S; MacNeil GA; Panchmatia R; Thompson JR; Sinha S; Warren JJ; Walsby CJ
    Inorg Chem; 2018 Dec; 57(24):15247-15261. PubMed ID: 30495936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of a highly tumor-selective organometallic ruthenium(II)-arene complex.
    Clavel CM; Păunescu E; Nowak-Sliwinska P; Griffioen AW; Scopelliti R; Dyson PJ
    J Med Chem; 2014 Apr; 57(8):3546-58. PubMed ID: 24669938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tuning of redox potentials for the design of ruthenium anticancer drugs -- an electrochemical study of [trans-RuCl(4)L(DMSO)](-) and [trans-RuCl(4)L(2)](-) complexes, where L = imidazole, 1,2,4-triazole, indazole.
    Reisner E; Arion VB; Guedes da Silva MF; Lichtenecker R; Eichinger A; Keppler BK; Kukushkin VY; Pombeiro AJ
    Inorg Chem; 2004 Nov; 43(22):7083-93. PubMed ID: 15500346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts.
    Chen H; Parkinson JA; Parsons S; Coxall RA; Gould RO; Sadler PJ
    J Am Chem Soc; 2002 Mar; 124(12):3064-82. PubMed ID: 11902898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anticancer activity of hydrogen-bond-stabilized half-sandwich Ru(II) complexes with heterocycles.
    Mitra R; Das S; Shinde SV; Sinha S; Somasundaram K; Samuelson AG
    Chemistry; 2012 Sep; 18(39):12278-91. PubMed ID: 22903299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
    Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
    Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dimetallic Ru(II) arene complexes appended on bis-salicylaldimine induce cancer cell death and suppress invasion via p53-dependent signaling.
    Rahman FU; Bhatti MZ; Ali A; Duong HQ; Zhang Y; Ji X; Lin Y; Wang H; Li ZT; Zhang DW
    Eur J Med Chem; 2018 Sep; 157():1480-1490. PubMed ID: 30282320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osmium-arene complexes with high potency towards Mycobacterium tuberculosis.
    Coverdale JPC; Guy CS; Bridgewater HE; Needham RJ; Fullam E; Sadler PJ
    Metallomics; 2021 Apr; 13(4):. PubMed ID: 33693931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands.
    Zhang Y; Zheng W; Luo Q; Zhao Y; Zhang E; Liu S; Wang F
    Dalton Trans; 2015 Aug; 44(29):13100-11. PubMed ID: 26106875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands.
    Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G
    Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of clusters from reactions of ruthenium arene anticancer complex with glutathione using nanoscale liquid chromatography Fourier transform ion cyclotron mass spectrometry combined with (18)O-labeling.
    Wang F; Weidt S; Xu J; Mackay CL; Langridge-Smith PR; Sadler PJ
    J Am Soc Mass Spectrom; 2008 Apr; 19(4):544-9. PubMed ID: 18222094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Organometallic ruthenium inhibitors of glutathione-S-transferase P1-1 as anticancer drugs.
    Ang WH; De Luca A; Chapuis-Bernasconi C; Juillerat-Jeanneret L; Lo Bello M; Dyson PJ
    ChemMedChem; 2007 Dec; 2(12):1799-806. PubMed ID: 17918761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Picolinate ruthenium(II)-arene complex with in vitro antiproliferative and antimetastatic properties: comparison to a series of ruthenium(II)-arene complexes with similar structure.
    Gligorijević N; Aranđelović S; Filipović L; Jakovljević K; Janković R; Grgurić-Šipka S; Ivanović I; Radulović S; Tešić ZLj
    J Inorg Biochem; 2012 Mar; 108():53-61. PubMed ID: 22266461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Highly Cytotoxic Ruthenium(II)-Arene Complexes from Bulky 1-Pyrenylphosphane Ligands.
    Brissos RF; Clavero P; Gallen A; Grabulosa A; Barrios LA; Caballero AB; Korrodi-Gregório L; Pérez-Tomás R; Muller G; Soto-Cerrato V; Gamez P
    Inorg Chem; 2018 Dec; 57(23):14786-14797. PubMed ID: 30444630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular delivery of pyrenyl-arene ruthenium complexes by a water-soluble arene ruthenium metalla-cage.
    Furrer MA; Schmitt F; Wiederkehr M; Juillerat-Jeanneret L; Therrien B
    Dalton Trans; 2012 Jun; 41(24):7201-11. PubMed ID: 22506276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Organometallic osmium(II) arene anticancer complexes containing picolinate derivatives.
    van Rijt SH; Peacock AF; Johnstone RD; Parsons S; Sadler PJ
    Inorg Chem; 2009 Feb; 48(4):1753-62. PubMed ID: 19146436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of
    Mukherjee A; Acharya S; Purkait K; Chakraborty K; Bhattacharjee A; Mukherjee A
    Inorg Chem; 2020 May; 59(9):6581-6594. PubMed ID: 32295347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Organometallic osmium arene complexes with potent cancer cell cytotoxicity.
    Fu Y; Habtemariam A; Pizarro AM; van Rijt SH; Healey DJ; Cooper PA; Shnyder SD; Clarkson GJ; Sadler PJ
    J Med Chem; 2010 Nov; 53(22):8192-6. PubMed ID: 20977192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioactive ruthenium(II)-arene complexes containing modified 18β-glycyrrhetinic acid ligands.
    Kong Y; Chen F; Su Z; Qian Y; Wang FX; Wang X; Zhao J; Mao ZW; Liu HK
    J Inorg Biochem; 2018 May; 182():194-199. PubMed ID: 29501980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Study of ruthenium(II) complexes with anticancer drugs as ligands. Design of metal-based phototherapeutic agents.
    Cini R; Tamasi G; Defazio S; Corsini M; Zanello P; Messori L; Marcon G; Piccioli F; Orioli P
    Inorg Chem; 2003 Dec; 42(24):8038-52. PubMed ID: 14632524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.